Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Bosch

Showing results (161-170 of 164) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 164 results.
Neuron|July 1, 1997
Proteolipid protein is necessary in peripheral as well as central myelinJ Y Garbern, F Cambi, X M Tang, et al.
Vox Sanguinis|September 16, 2010
Adverse reactions during transfusion of thawed haematopoietic progenitor cells from apheresis are closely related to the number of granulocyte cells in the leukapheresis productG A Martín-Henao, P M Resano, J M S Villegas, et al.
Neurology|April 11, 2001
Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosisR G Miller, D H Moore, D F Gelinas, et al.
Neurology|November 26, 2008
Subcutaneous IGF-1 is not beneficial in 2-year ALS trialE J Sorenson, A J Windbank, J N Mandrekar, et al.
Pageof 17

Showing results (161-170 of 164) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 164 results.
Neuron|July 1, 1997
Proteolipid protein is necessary in peripheral as well as central myelinJ Y Garbern, F Cambi, X M Tang, et al.
Vox Sanguinis|September 16, 2010
Adverse reactions during transfusion of thawed haematopoietic progenitor cells from apheresis are closely related to the number of granulocyte cells in the leukapheresis productG A Martín-Henao, P M Resano, J M S Villegas, et al.
Neurology|April 11, 2001
Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosisR G Miller, D H Moore, D F Gelinas, et al.
Neurology|November 26, 2008
Subcutaneous IGF-1 is not beneficial in 2-year ALS trialE J Sorenson, A J Windbank, J N Mandrekar, et al.
Pageof 17